pixantrone

Pixantrone is a synthetic aza-anthracenedione antineoplastic agent developed as an alternative to traditional anthracyclines for the treatment of relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). It acts primarily by intercalating into DNA and forming stable DNA adducts and cross-strand breaks. Unlike other anthracyclines and anthracenediones, it is only a weak inhibitor of topoisomerase II but directly alkylates DNA. Its unique structure reduces its ability to generate reactive oxygen species, bind iron, or form cardiotoxic metabolites—resulting in significantly less cardiac toxicity compared to doxorubicin or mitoxantrone. Pixantrone was designed for patients who have failed at least two prior lines of therapy for aggressive NHL and cannot tolerate further cumulative cardiotoxicity from standard agents. It has also been investigated in other hematologic malignancies and solid tumors[1][3][4][5].

Brand names

Pixuvri

Other names

pixantrone dimaleate